Immunomedics Inc - Company Profile
Powered by 
All the sales intelligence you need on Immunomedics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Immunomedics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Immunomedics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on Immunomedics Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| CN117138060A | Application | 抗体-药物缀合物的新辅助剂用途 | A61K31/4745; A61K31/704; A61K45/06; A61K47/6803; A61K47/6809; A61K47/6811; A61K47/6849; A61K47/6851; A61K47/6853; A61K47/6867; A61P35/00; A61P35/02; A61P35/04; A61P43/00 | December 01, 2023 |
| ES2953441T3 | Grant | Combinación de anticuerpos anti-hla-dr o anti-trop-2 con inhibidores de microtúbulos, inhibidores de parp, inhibidores de la cinasa de bruton o inhibidores de la fosfoinositida 3-cinasa mejora significativamente el resultado terapéutico en el cáncer | A61K2039/505; A61K2039/545; A61K31/337; A61K31/357; A61K31/4745; A61K31/502; A61K31/519; A61K31/52; A61K39/395; A61K39/3955; A61K39/39558; A61K45/06; A61K47/6803; A61K47/6849; A61K47/6851; A61K47/6853; A61K47/6889; A61P35/00; A61P35/02; A61P35/04; A61P43/00; C07K16/2803; C07K16/2887; C07K16/30; C07K16/3007; C07K2317/24; C07K2317/73; C07K2317/732; C07K2317/94 | November 13, 2023 |
| PL3313443T3 | Grant | Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer | A61K2039/505; A61K2039/545; A61K31/337; A61K31/357; A61K31/4745; A61K31/502; A61K31/519; A61K31/52; A61K39/395; A61K39/3955; A61K39/39558; A61K45/06; A61K47/6803; A61K47/6849; A61K47/6851; A61K47/6853; A61K47/6889; A61P35/00; A61P35/02; A61P35/04; A61P43/00; C07K16/2803; C07K16/2887; C07K16/30; C07K16/3007; C07K2317/24; C07K2317/73; C07K2317/732; C07K2317/94 | November 06, 2023 |
| HUE062339T2 | Application | Immunoconjugates with an intracellularly-cleavable linkage | A61P37/02; A61P31/12; A61P29/00; A61P31/18; A61K31/4745; A61K47/6855; Y02A50/30; A61K47/6859; C07K16/1063; A61K2039/505; C07K16/3092; C07K2317/53; A61P31/04; A61K47/6849; A61K47/6853; A61K47/6857; A61K47/6861; A61P17/00; A61N5/10; C07K16/3046; A61K47/6803; C07K16/30; A61K47/6841; C07K2317/31; C07D491/22; A61P35/00; C07K16/2863; C07K2317/21; C07K16/2803; C07K16/3076; A61P31/00; C07K2317/24; A61K47/6851; A61K45/06; C07K2317/94; C07K16/2887; C07K16/18; C07K16/303; C07K2317/40; C07K2317/52; A61P35/04; A61P37/06; A61K47/6889; C07K16/2833 | October 28, 2023 |
| EP4257134A2 | Application | Kombination von anti-hla-dr- oder anti-trop-2-antikörpern mit mikrotubuli-inhibitoren, parp-inhibitoren, bruton-kinase-inhibitoren oder phosphoinositol-3-kinase-inhibitoren zur signifikanten verbesserung des therapeutischen ergebnisses bei krebs | A61K2039/505; A61K2039/545; A61K31/337; A61K31/357; A61K31/4745; A61K31/502; A61K31/519; A61K31/52; A61K39/395; A61K39/3955; A61K39/39558; A61K45/06; A61K47/6803; A61K47/6849; A61K47/6851; A61K47/6853; A61K47/6889; A61P35/00; A61P35/02; A61P35/04; A61P43/00; C07K16/2803; C07K16/2887; C07K16/30; C07K16/3007; C07K2317/24; C07K2317/73; C07K2317/732; C07K2317/94 | October 11, 2023 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer